Erythrocyte membrane-encapsulated SZF nanocomposites for hyperuricemia therapy
The erythrocyte membrane-camouflaged SZF@PDA‑RM nanocomposite achieves long circulation and targeted delivery. It exerts a multi-target synergistic therapeutic effect by directly scavenging ROS, maintaining mitochondrial homeostasis via the SHP2/ANT1 pathway, and inhibiting NLRP3-mediated inflammation, thereby effectively improving uric acid metabolism and alleviating renal injury.
Authors
- Guangjin Pu
- Yuke Zeng
- Dongdong Li (ORCID: https://orcid.org/0000-0002-6648-3311)
- luobing wang
- Jiandong Gao (ORCID: https://orcid.org/0000-0001-8978-2982)
- Chengjie Zhang (ORCID: https://orcid.org/0000-0001-6885-1678)
- Xin Guan (ORCID: https://orcid.org/0000-0003-2618-1586)
- Jing Hu
- Weiwei Liu
- Boyi Shen
Institutions
- Tongji University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Second Affiliated Hospital of Zhengzhou University (CN)
- Traditional Chinese Medicine Hospital of Kunshan (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- Seventh People's Hospital of Shanghai (CN)
- Shuguang Hospital (CN)
- First Affiliated Hospital of Henan University (CN)
- Xiangyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1695253
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Shanghai University of Traditional Chinese Medicine